Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Acute exacerbation of idiopathic pulmonary fibrosis: International survey and call for harmonisation.

Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T, Flaherty K, Funke-Chambour M, Kolb M, Kondoh Y, Maher TM, Molina MM, Morais A, Moor CC, Morisset J, Pereira C, Quadrelli S, Selman M, Tzouvelekis A, Valenzuela C, Vancheri C, Vicens-Zygmunt V, Wälscher J, Wuyts W, Wijsenbeek M, Cottin V, Bendstrup E.

Eur Respir J. 2020 Feb 14. pii: 1901760. doi: 10.1183/13993003.01760-2019. [Epub ahead of print]

PMID:
32060068
2.

[Idiopathic pulmonary fibrosis-epidemiology, causes, and clinical course].

Schäfer SC, Funke-Chambour M, Berezowska S.

Pathologe. 2020 Feb;41(1):46-51. doi: 10.1007/s00292-019-00747-x. Review. German.

PMID:
31993696
3.

Correction to: Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls.

Krempaska K, Barnowski S, Gavini J, Hobi N, Ebener S, Simillion C, Stokes A, Schliep R, Knudsen L, Geiser TK, Funke-Chambour M.

Respir Res. 2020 Jan 28;21(1):29. doi: 10.1186/s12931-020-1304-7.

4.

Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected].

Krempaska K, Barnowski S, Gavini J, Hobi N, Ebener S, Simillion C, Stokes A, Schliep R, Knudsen L, Geiser TK, Funke-Chambour M.

Respir Res. 2020 Jan 15;21(1):25. doi: 10.1186/s12931-020-1275-8. Erratum in: Respir Res. 2020 Jan 28;21(1):29.

5.

[Diagnostics of interstitial lung diseases in the multidisciplinary team].

Berezowska S, Pöllinger A, Funke-Chambour M.

Ther Umsch. 2019;76(7):375-381. doi: 10.1024/0040-5930/a001105. Review. German.

PMID:
31913096
6.

[The multidisciplinary discussion-the gold standard in diagnosing interstitial lung diseases].

Berezowska S, Funke-Chambour M, Pöllinger A, Schäfer SC.

Pathologe. 2020 Feb;41(1):14-20. doi: 10.1007/s00292-019-00725-3. Review. German.

PMID:
31858183
7.

New radiological diagnostic criteria: impact on idiopathic pulmonary fibrosis diagnosis.

Funke-Chambour M, Guler SA, Geiser T, Christe A, Heverhagen J, Pöllinger A, Huber A, Ebner L.

Eur Respir J. 2019 Nov 7;54(5). pii: 1900905. doi: 10.1183/13993003.00905-2019. Print 2019 Nov. No abstract available.

PMID:
31273039
8.

Antifibrotics: Shrinking the Box of Therapeutic Uncertainty.

Guler SA, Funke-Chambour M.

Respiration. 2019;97(3):202-204. doi: 10.1159/000494275. Epub 2018 Nov 19. No abstract available.

PMID:
30453286
9.

Medium throughput breathing human primary cell alveolus-on-chip model.

Stucki JD, Hobi N, Galimov A, Stucki AO, Schneider-Daum N, Lehr CM, Huwer H, Frick M, Funke-Chambour M, Geiser T, Guenat OT.

Sci Rep. 2018 Sep 25;8(1):14359. doi: 10.1038/s41598-018-32523-x.

10.

Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre.

Guler S, Zumstein P, Berezowska S, Pöllinger A, Geiser T, Funke-Chambour M.

Swiss Med Wkly. 2018 Jan 4;148:w14577. doi: 10.4414/smw.2018.14577. eCollection 2018.

11.

Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis - a potential biomarker role for LysoPC.

Rindlisbacher B, Schmid C, Geiser T, Bovet C, Funke-Chambour M.

Respir Res. 2018 Jan 10;19(1):7. doi: 10.1186/s12931-018-0714-2.

12.

Novel insights in cough and breathing patterns of patients with idiopathic pulmonary fibrosis performing repeated 24-hour-respiratory polygraphies.

Schertel A, Funke-Chambour M, Geiser T, Brill AK.

Respir Res. 2017 Nov 13;18(1):190. doi: 10.1186/s12931-017-0674-y.

13.

Perioperative Lung Function Monitoring for Anatomic Lung Resections.

Kocher GJ, Gioutsos KP, Ahler M, Funke-Chambour M, Ott SR, Dorn P, Lutz J, Schmid RA.

Ann Thorac Surg. 2017 Nov;104(5):1725-1732. doi: 10.1016/j.athoracsur.2017.06.018. Epub 2017 Sep 28.

PMID:
28964423
14.

Pharmakologische und nicht-pharmakologische Therapie der idiopathischen Lungenfibrose.

Schertel A, Funke-Chambour M, Geiser T.

Praxis (Bern 1994). 2017 Sep;106(18):999-1006. doi: 10.1024/1661-8157/a002770. German. No abstract available.

PMID:
28875747
15.

Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis-a pilot study.

Rindlisbacher B, Strebel C, Guler S, Kollár A, Geiser T, Martin Fiedler G, Benedikt Leichtle A, Bovet C, Funke-Chambour M.

J Breath Res. 2017 Nov 29;12(1):016003. doi: 10.1088/1752-7163/aa840a.

16.

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment.

Funke-Chambour M, Azzola A, Adler D, Barazzone-Argiroffo C, Benden C, Boehler A, Bridevaux PO, Brutsche M, Clarenbach CF, Hostettler K, Kleiner-Finger R, Nicod LP, Soccal PM, Tamm M, Geiser T, Lazor R.

Respiration. 2017;93(5):363-378. doi: 10.1159/000464332. Epub 2017 Mar 25.

17.

Multidisciplinary discussion for diagnosis of interstitial lung disease in real life.

Guler SA, Berezowska SA, Christe A, Geiser T, Funke-Chambour M.

Swiss Med Wkly. 2016 Jun 1;146:w14318. doi: 10.4414/smw.2016.14318. eCollection 2016. No abstract available.

18.

[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].

Funke-Chambour M, Geiser T.

Ther Umsch. 2016;73(1):25-9. doi: 10.1024/0040-5930/a000751. Review. German.

PMID:
26884217
19.

[Rare pathogens causing pneumonia].

Funke-Chambour M, Ott SR.

Dtsch Med Wochenschr. 2013 Oct;138(40):2019-22. doi: 10.1055/s-0033-1349509. Epub 2013 Sep 24. German. No abstract available.

PMID:
24065408

Supplemental Content

Loading ...
Support Center